【New Publication】Suppressing MASH Progression Using the STAM Mouse Model
A recent study using the STAM™ mouse model demonstrates clear efficacy in MASH progression inhibition – this could support your preclinical strategy.
▶ Publication:
Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH
In this paper, the authors highlight the effect of 2-HOBA, a scavenger of reactive dicarbonyl electrophiles (DE), in improving MASH by reducing oxidative stress, inflammation, and mitochondrial dysfunction in the liver.
Notably, a significant reduction in the NAFLD activity score, one of the key endpoints in MASH studies, was observed.
Why choose the STAM™ model?:
- Reproducible MASH pathology for multi-pathway evaluation
- Clinically relevant for comprehensive single-study assessment
- Ideal for both HCC prevention and treatment studies
SMC offer the following support for your MASH-related research:
✅ Evaluation studies from MASH to HCC stages using the STAM™ model
✅ Comparative studies with approved therapeutics such as resmetirom
✅ Custom study designs using alternative MASH models (e.g., diet-induced models) to cover a broader range of human disease features
If you are currently considering the evaluation of a new drug candidate for MASH or related indications, we would be happy to assist.
We would be glad to propose a suitable study design based on your development stage and objectives.